newsfilter
← Latest News
GlobeNewswire·

Caribou Biosciences to Evaluate Strategic Alternatives

-- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs -- -- Cash, cash equivalents, and marketable